

Huntsville Hospital Heart Centre confirmed as participant in SAPPHIRE Study

SAPPHIRE Study on track to commence in early 2026 with 6 – 8 high volume U.S. centres

PERTH, Australia, 07 October 2025: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix[®] AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that Huntsville Hospital Heart Centre (HH Heart Centre), part of Huntsville Hospital Health System, one of the largest not-for-profit health systems in Alabama, has agreed to be a participant in the retrospective U.S. multi-centre SAPPHIRE Study, subject to final documentation and their ethics approval.

Highlights

- Huntsville Hospital Heart Centre confirms in-principle participation as a collaborator in the SAPPHIRE Study.
- Huntsville Hospital Health System is one of the largest providers in Alabama and Tennessee, comprising 14 hospitals and managing over 420,000 emergency visits and 1.21 million outpatient procedures.
- The system specialises in advanced cardiovascular care, with multiple trials underway and a world-leading Photon Counting CT scanner providing high-resolution coronary imaging ideal for the SAPPHIRE Study.
- The SAPPHIRE Study now includes Piedmont Healthcare and Huntsville as two of the planned 6–8 major, high-volume U.S. centres, expected to commence in early 2026 to evaluate patients at risk of coronary artery disease using Salix[®] and Artrya's novel Plaque Dispersion Score.

John Konstantopoulos, Co-Founder and CEO of Artrya commented:

"We are pleased to announce the Huntsville Hospital Heart Centre as our latest partner in the SAPPHIRE Study. Their extensive presence across the southern United States and active participation in a number of cardiovascular clinical trials will enhance the Study's reach and clinical relevance. With both Huntsville Hospital Heart Centre and Piedmont Healthcare now on board, we will be collaborating with two prominent health systems in the U.S. to continue to lay the groundwork for clinical adoption. The SAPPHIRE Study remains on schedule to launch in early 2026, pending finalisation of contracting and ethics approvals with our targeted cohort of 6 to 8 participating sites."

Michael L. Ridner, MD, FACC, Head of Cardiology for the Huntsville Hospital Heart Centre:

"The SAPPHIRE Study provides an opportunity to explore new frontiers in cardiovascular care. By applying Artrya's advanced AI solutions, including the Plaque Dispersion Score, we can improve our understanding of coronary risk at the individual level. Huntsville Hospital Heart Centre is committed to leveraging innovation to improve patient outcomes, and we are pleased to partner with Artrya on this important initiative."

SAPPHIRE Study on target for launch in early 2026 with addition of HH Heart Centre

The inclusion of Huntsville Hospital Heart Centre alongside Piedmont Healthcare as another major, high-volume U.S. cardiology centre represents a significant step forward toward the commencement of the SAPPHIRE Study, scheduled for early 2026. The Salix[®]-based Analysis of Plaque to Identify Patients at Higher Risk of Events (SAPPHIRE) Study is a retrospective, multi-centre, real-world study designed to evaluate the prognostic and clinical utility of Artrya's Salix[®] Plaque Analysis and the proprietary Plaque Dispersion Score (PDS).

Huntsville Hospital Heart Centre is a recognised regional leader in cardiovascular care, combining extensive patient reach with strong clinical research capabilities. The Centre is a leading clinical research organisation specialising in cardiovascular studies, having successfully completed more than 400 Phase II–IV clinical trials, primarily in cardiology, with additional expertise in nephrology, pulmonology, and cardiothoracic surgery.

In collaboration with Huntsville Hospital, the HH Heart Centre research team currently supports 42 active studies and partners with 27 experienced cardiologist investigators. With its advanced cardiovascular expertise and significant trial activity in cardiovascular disease, the HH Heart Centre is ideally positioned as a collaborator in the SAPPHIRE Study.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com